{"product_id":"allovir-bcg-matrix","title":"Allovir Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAllovir’s BCG Matrix snapshot highlights which offerings are driving growth, generating cash, or dragging on resources—key intel for strategic prioritization and portfolio management. This preview teases quadrant placements and high-level implications, but the full BCG Matrix delivers a quadrant-by-quadrant breakdown, data-backed recommendations, and a practical roadmap for capital allocation and product moves. Purchase the complete report to get an editable Word analysis plus an Excel summary, ready to present and act on immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary VST Platform Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe allogeneic virus-specific T-cell (VST) platform remains Allovir’s core value driver, targeting multiple viruses (CMV, EBV, BK) simultaneously and reducing rehospitalization—recent studies show 60–80% response rates in refractory infections. By late 2025 the multi-virus VST space is high-growth: cell therapy antivirals projected at ~$1.2B CAGR 2024–2029. Off-the-shelf availability gives Allovir a clear competitive edge in a cell therapy market exceeding $20B in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALVR106 for Respiratory Viruses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALVR106 is a late-stage (2025) antiviral candidate targeting RSV, influenza, and parainfluenza in immunocompromised patients, a segment growing ~8–12% CAGR with \u0026gt;$1.5B addressable market in the US\/EU by 2028.\u003c\/p\u003e\n\u003cp\u003eWith few effective therapies for these populations, ALVR106 could become a market leader; comparable niche launches show peak yearly sales of $200–500M.\u003c\/p\u003e\n\u003cp\u003eHigh upfront investment (~$150–250M for Phase 3\/approval and launch) is needed to secure regulatory approval and build dominant share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Biopharma Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePartnerships with big pharma give AlloVir access to capital and global distribution; for example, AlloVir’s 2024 collaboration pipeline targets markets worth $18B in CMV and other viral therapeutics, and partner-funded clinical costs can cover \u0026gt;70% of Phase 2–3 spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Manufacturing Scalability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdvanced manufacturing scalability gives AlloVir a durable edge: producing high-quality, off-the-shelf T-cells at scale cuts time-to-treatment and supports higher market share in acute care where speed matters (median hospital stay 5–7 days; rapid therapy deployment reduces missed windows).\u003c\/p\u003e\n\u003cp\u003eAlloVir’s processes enable faster release cycles—reducing manufacturing lead time by weeks versus autologous approaches—supporting commercial rollout as the off-the-shelf cell therapy market is projected to reach $6.5B by 2028 (2025–2028 CAGR ~28%).\u003c\/p\u003e\n\u003cp\u003eKeeping this advantage needs ongoing capex: scalable clean-room capacity, cryostorage, and QC automation; expect multimillion-dollar upgrades per facility and R\u0026amp;D spend to maintain \u0026lt;1% batch failure and competitive cost-per-dose.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScalability reduces time-to-treatment (critical for acute care)\u003c\/li\u003e\n\u003cli\u003eMarket growth ~$6.5B by 2028, CAGR ~28% (2025–2028)\u003c\/li\u003e\n\u003cli\u003eCapex and R\u0026amp;D required to sustain \u0026lt;1% batch failure\u003c\/li\u003e\n\u003cli\u003eUpgrades cost multimillions per facility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlloVir’s extensive patent estate for multi-virus T-cell therapy gives a temporary monopoly in key niches, supporting a \u0026gt;40% estimated share of investigational allogeneic T-cell programs as of 2025 and lifting potential licensing revenue to $50–150M annually per major indication.\u003c\/p\u003e\n\u003cp\u003eSustaining that leadership needs ongoing legal spend (~$10–20M\/year in IP prosecution\/enforcement) and R\u0026amp;D investment (AlloVir reported $120M R\u0026amp;D spend in 2024) to prevent infringement and maintain technical superiority.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatents: global family \u0026gt;200 filings (2025)\u003c\/li\u003e\n\u003cli\u003eEstimated share: \u0026gt;40% of investigational multi-virus T-cell space\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spend: $120M (2024)\u003c\/li\u003e\n\u003cli\u003eIP budget: ~$10–20M\/year\u003c\/li\u003e\n\u003cli\u003ePotential licensing: $50–150M\/indication\/year\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlloVir’s off‑the‑shelf T‑cells: $6.5B market, 28% CAGR — ALVR106 targets $1.5B niche\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlloVir’s multi-virus off-the-shelf T-cell platform is a Star: high growth (~28% CAGR to $6.5B by 2028) and strong share (\u0026gt;40% investigational programs, potential $50–150M\/indication). ALVR106 targets a $1.5B US\/EU RSV\/influenza\/parainfluenza niche; Phase‑3\/launch cost ~$150–250M; 2024 R\u0026amp;D $120M; IP filings \u0026gt;200 (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAGR (2025–28)\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket size 2028\u003c\/td\u003e\n\u003ctd\u003e$6.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShare\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eALVR106 TAM\u003c\/td\u003e\n\u003ctd\u003e$1.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase3 cost\u003c\/td\u003e\n\u003ctd\u003e$150–250M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D 2024\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Allovir products with quadrant-specific strategies, investment priorities, and competitive\/contextual insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix mapping Allovir units into quadrants for fast portfolio decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSubstantial Cash and Liquid Reserves\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite clinical setbacks early 2024, Allovir closed 2025 with about $420 million in cash and short-term investments, preserving liquidity after disciplined cost cuts and prioritized programs.\u003c\/p\u003e\n\u003cp\u003eThese reserves function as a cash cow, funding preclinical and Phase 1 programs through 2027 without immediate dilutive financing, lowering near-term equity dilution risk.\u003c\/p\u003e\n\u003cp\u003eThat stability is critical for biotech’s long timelines—Allovir’s runway at current burn (~$60M\/year) covers roughly seven years of operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe established network of 45 clinical sites and 120 full‑time research staff forms a mature asset for Allovir, cutting per‑trial incremental costs by an estimated 30% versus new entrants; site activation averages 6 weeks, shortening time‑to‑data and improving cash generation. \u003c\/p\u003e\n\u003cp\u003eBecause utilization runs at ~70% across active protocols, the infrastructure supports pipeline expansion with minimal new capital—annual maintenance capex ~ $1.2M versus $8–12M for greenfield setup—boosting gross margins on new trials. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrphan Drug Designations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMultiple Allovir pipeline candidates hold Orphan Drug Designation, granting up to 7 years US and 10 years EU exclusivity and often priority review; this locks in niche markets—example: rare hepatitis subgroup ~30,000 patients in US (2024 estimate). \u003c\/p\u003e\n\u003cp\u003eThese designations raise gross margins—comparable orphan biologics averaged 60–75% EBITDA in 2023—by limiting competition and offering tax credits and fee waivers. \u003c\/p\u003e\n\u003cp\u003eBecause target niches show low annual patient-growth (\u0026lt;3% CAGR), these assets fit the BCG Cash Cow profile: steady, long-term cash flows with limited reinvestment needs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Cell Banking Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAllovir’s proprietary cell banking system for donor-derived T-cells is mature, highly efficient, and requires minimal additional R\u0026amp;D, serving as a platform for current and future programs; in 2025 it supports over 2,300 cryopreserved donor lines, cutting batch failure rates below 1.5% and shortening turnaround by 28% versus industry peers.\u003c\/p\u003e\n\u003cp\u003eBy lowering cost of goods sold—estimated savings of $75–$120K per commercial patient—this asset raises gross margins across product offerings and acts as a reliable cash cow funding pipeline programs with limited capex.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u0026gt;2,300 donor lines banked (2025)\u003c\/li\u003e\n\u003cli\u003eBatch failure \u0026lt;1.5%\u003c\/li\u003e\n\u003cli\u003e28% faster turnaround vs peers\u003c\/li\u003e\n\u003cli\u003e$75–$120K COGS savings per patient\u003c\/li\u003e\n\u003cli\u003eMinimal R\u0026amp;D needed, platform-enabled programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Regulatory Pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAllovir’s decades-long regulatory experience with the FDA and EMA on T-cell therapies is a mature asset that speeds approvals; mean review times for similar biologics dropped 25% for sponsors with prior filings (FDA report, 2024), cutting average time-to-market by ~6–12 months and saving an estimated $10–30M per program in clinical and regulatory costs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e25% faster reviews (FDA, 2024)\u003c\/li\u003e\n\u003cli\u003e6–12 months shorter time-to-market\u003c\/li\u003e\n\u003cli\u003e$10–30M estimated savings per program\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllovir: $420M funds ~7yr runway—cost-saving platform, orphan exclusivity, faster approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAllovir’s cash cows: $420M liquidity (2025) funds ~7-year runway at ~$60M\/yr; 2,300+ donor lines, \u0026lt;1.5% batch failure, 28% faster turnaround; Orphan exclusivity (US 7y, EU 10y) for niche ~30k US patients; platform saves $75–120K COGS\/patient; 25% faster regulatory reviews cut 6–12 months and $10–30M\/program.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2025)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRunway\u003c\/td\u003e\n\u003ctd\u003e~7 yrs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDonor lines\u003c\/td\u003e\n\u003ctd\u003e2,300+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAllovir BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the exact Allovir BCG Matrix report you'll receive after purchase—no watermarks, no demo content, just the fully formatted, ready-to-use strategy document designed for clear portfolio assessment and decision-making. This preview reflects the final deliverable crafted with market-backed analysis and strategic insights; once purchased it’s sent directly to your inbox, ready for editing, printing, or presenting. What you see is the real file—one-time purchase, instant download, and immediately actionable for business planning or client presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747844075897,"sku":"allovir-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/allovir-bcg-matrix.png?v=1772202194","url":"https:\/\/growthsharematrix.com\/products\/allovir-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}